Zobrazeno 1 - 10
of 20
pro vyhledávání: '"J. M. Guliana"'
Autor:
Gérard Milhaud, N. Segond, F. Lasmoles, M.S. Moukhtar, C. Calmettes, M.C. Delehaye, Stephane Minvielle, Régis Cohen, J. M. Guliana
Publikováno v:
FEBS Letters. 277:243-246
Two genes code for calcitonin gene-related peptides (CGRPs). One expresses by tissue-specific alternate splicing calcitonin and CGRP I mRNAs, the other CGRP II mRNA. Calcitonin is the marker of sporadic or hereditary human medullary thyroid carcinoma
Autor:
Jean-Alain Chayvialle, C. Bernard, R. Cohen, C. Alamowitch, E. Modigliani, Franc B, C. Calmettes, J. M. Guliana
Publikováno v:
Cancer. 65:224-228
The current work has been performed by the Cooperative French Group of Medullary Thyroid Carcinoma (GETC). A systematic evaluation of RIA somatostatin (SRIH) was performed in 34 medullary thyroid carcinomas (MTC) (25 inherited, seven sporadic). Plasm
Autor:
Annick Jullienne, E. Pidoux, J. M. Guliana, Régis Delage-Mourroux, Franck Pichaud, Jean-Louis Frendo, Régis Cohen
Publikováno v:
Molecular and cellular endocrinology. 139(1-2)
Among the four isoforms of the calcitonin receptor (CTR) described in humans, two differ by the presence of h-CTR1 or absence of h-CTR2 of 16 amino acids in the first intracellular loop. Both receptors are biologically active. The TT cell line derive
Autor:
Jean-Louis Frendo, E. Pidoux, Régis Delage-Mourroux, M.S. Moukhtar, Franck Pichaud, Annick Jullienne, J. M. Guliana
Publikováno v:
Gene. 188(1)
NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (type-I 15-PGDH) inactivates prostaglandins. We recently reported an mRNA sequence coding for a predicted isomer (PGDH(rI)) of this enzyme. The TT cell line, derived from medullary thyroid carcinom
Autor:
J M, Guliana
Publikováno v:
Annales d'endocrinologie. 57(1)
Medullary thyroid carcinoma (MTC) is a rare endocrine tumour secreting the calcitonin (CT), its main tumoral marker, occuring as a sporadic or a familial disease. These diseases are associated with a 5-years prognostic from less than 50 to 100%, depe
Autor:
R, Cohen, M C, Delehaye, S, Minvielle, N, Segond, J, Taboulet, M, Noel, J M, Guliana, C, Calmettes, G, Milhaud, F, Lasmoles
Publikováno v:
Biochemical and biophysical research communications. 185(1)
We have recently identified in medullary thyroid carcinoma the existence of a second calcitonin messenger, generated by a splicing between the 3' coding region of exon 4 and exon 5 of Calc I gene. It differs from the first one in its 3' coding sequen
Autor:
P. J. Gulllausseau, P. Aulévre, Ph. Caron, M. Bentala Pessayre, G. Charpentier, P. Roger, E. Modlgliani, C. Slame-Mourot, S. Joannldis, Antoine Tabarin, A. James-Deldier, J. D. Lalau, J. Tournlafre, F. Bayard, J. M. Guliana, D. Cassuto, C. Catmettest, Régis Cohen
Publikováno v:
Clinical endocrinology. 36(2)
SUMMARY objective Treatment by octreotide has been suggested In medullary thyroid carcinoma patients with post-surgery metastases. The purpose of this study was to evaluate If the tumoral regression could be Improved by a high dose and by prolonged o
Autor:
E, Modigliani, C, Alamowitch, R, Cohen, C, Calmettes, J M, Guliana, B, Franc, C, Bernard, J A, Chayvialle
Publikováno v:
Cancer. 65(2)
The current work has been performed by the Cooperative French Group of Medullary Thyroid Carcinoma (GETC). A systematic evaluation of RIA somatostatin (SRIH) was performed in 34 medullary thyroid carcinomas (MTC) (25 inherited, seven sporadic). Plasm
Autor:
Annick Jullienne, J. Chenais, J.M. Le Moullec, J. M. Guliana, Gérard Milhaud, F. Lasmoles, M.S. Moukhtar
Publikováno v:
FEBS Letters. 167:93-97
DNA complementary to mRNA extracted from the thyroid glands of patients suffering from medullary carcinoma of the thyroid (MCT), a calcitonin-producing tumour, was inserted in the Pst site of pBR 322 by G-C tailing. The recombinant plasmids were used
Autor:
J. Caron, C. Calmettes, E. Modigliani, Pierre-Jean Guillausseau, J. M. Guliana, C. Siame-Mourot
Publikováno v:
Hormone and Metabolic Research. 21:584-586
This study is in favour of a real effect of SNS 201995 on calcitorin levels. This effect seems more effective in patients with less extensive medutary thyroid carcinoma (MTC). This suggests that SMS 201995 could be limited to the less aggressive form